The median survival period of chemotherapy alone for mid to late stage lung cancer is 9-10 months, that is, only 50 out of 100 patients can live beyond 9-10 months, and the one-year survival rate is about 34.8%. The response to chemotherapy in the middle and late stages of lung cancer is poor. For patients with advanced and recurrent lung cancer, combination chemotherapy regimens can only aim to relieve symptoms and improve quality of life and extend life expectancy. Currently, first-line chemotherapy is recommended to combine two platinum-containing drugs, such as carboplatin or cisplatin plus paclitaxel, vincristine, gemcitabine, pemetrexed, docetaxel, etc. for 4-6 cycles. For patients whose tumors are in remission or whose disease is stable without progression after chemotherapy, maintenance therapy can be given, which can prolong the survival of some patients. .